About Standard BioTools Inc.
https://www.standardbio.comStandard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics.
CEO
Michael Egholm
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
CASDIN CAPITAL, LLC
Shares:77.56M
Value:$123.32M
VIKING GLOBAL INVESTORS LP
Shares:58.65M
Value:$93.26M
BLACKROCK, INC.
Shares:24.92M
Value:$39.62M
Summary
Showing Top 3 of 173
About Standard BioTools Inc.
https://www.standardbio.comStandard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $19.55M ▼ | $32.95M ▼ | $-34.69M ▼ | -177.41% ▼ | $-0.09 ▼ | $-31.29M ▼ |
| Q2-2025 | $21.76M ▼ | $36.33M ▼ | $-33.46M ▼ | -153.75% ▼ | $-0.09 ▼ | $-14.28M ▲ |
| Q1-2025 | $40.8M ▼ | $52.71M ▼ | $-26.03M ▲ | -63.81% ▲ | $-0.07 ▲ | $-22.01M ▲ |
| Q4-2024 | $46.72M ▲ | $54.72M ▼ | $-34.07M ▼ | -72.93% ▼ | $-0.09 ▼ | $-26.02M ▼ |
| Q3-2024 | $44.97M | $54.98M | $-26.94M | -59.9% | $-0.07 | $-20.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $194.9M ▼ | $539.64M ▼ | $139.98M ▲ | $399.66M ▼ |
| Q2-2025 | $237.09M ▼ | $556.97M ▼ | $132.43M ▲ | $424.54M ▼ |
| Q1-2025 | $258.06M ▼ | $579.6M ▼ | $125M ▼ | $454.6M ▼ |
| Q4-2024 | $292.87M ▼ | $612.34M ▼ | $140.62M ▼ | $471.72M ▼ |
| Q3-2024 | $366.33M | $681.54M | $192.21M | $489.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.69M ▼ | $-22.2M ▼ | $-6.68M ▼ | $-112K ▼ | $-29.2M ▼ | $-23.09M ▼ |
| Q2-2025 | $-33.46M ▼ | $-20.67M ▲ | $27.5M ▲ | $108K ▲ | $7.73M ▲ | $-22.55M ▲ |
| Q1-2025 | $-26.03M ▲ | $-30.28M ▼ | $14.63M ▼ | $-46K ▲ | $-15.35M ▲ | $-35.34M ▼ |
| Q4-2024 | $-34.07M ▼ | $-14.06M ▲ | $25.73M ▲ | $-54.52M ▼ | $-43.12M ▲ | $-17.44M ▲ |
| Q3-2024 | $-26.94M | $-27.87M | $-30.88M | $-2K | $-59.16M | $-30.12M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Collaboration and Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Consumables | $40.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Instruments | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $50.00M ▲ | $10.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Product And Service | $80.00M ▲ | $0 ▼ | $0 ▲ | $40.00M ▲ |
 Service | $40.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
 Service and Other Revenue | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas | $50.00M ▲ | $20.00M ▼ | $10.00M ▼ | $10.00M ▲ |
 Asia Pacific | $20.00M ▲ | $10.00M ▼ | $0 ▼ | $0 ▲ |
 EMEA | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
CEO
Michael Egholm
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
CASDIN CAPITAL, LLC
Shares:77.56M
Value:$123.32M
VIKING GLOBAL INVESTORS LP
Shares:58.65M
Value:$93.26M
BLACKROCK, INC.
Shares:24.92M
Value:$39.62M
Summary
Showing Top 3 of 173